← Sino Medical Sciences Technology In overview

Sino Medical Sciences Technology In vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sino Medical Sciences Technology In (688108.CG)

Q3 202624 Jul – 9 Oct 2026

▲4

Sino Medical's profit surge and overseas approvals drive the story

First-half profit jumps on coronary and neuro product sales Sino Medical said first-half 2026 net profit should rise about 264% to 50.3 million yuan, as its coronary products sold more and new neuro products grew strongly, with revenue up about 27% and costs controlled. That profit growth is the main force pushing the stock up.
This is the core earnings driver behind the period's move.
Interim report confirms the profit jump and healthy cash flow The actual interim report matched the forecast: 305 million yuan revenue, 50.3 million yuan net profit, and 94 million yuan of cash coming in from operations. A low debt ratio and 70% gross margin show the business is profitable and not stretched, supporting the shares.
It confirms the earnings surprise with real numbers and cash flow.
Overseas approvals open new markets for heart devices Sino Medical won registration for its coronary balloon catheter in Vietnam and Colombia, letting it sell these heart products in those countries. Each approval is a small but real step in overseas expansion, adding future sales that support the stock price.
New market approvals are a fresh growth path for the company.
H-share listing plan and Paraguay stent approval add capital and reach Sino Medical is filing to issue H-shares in Hong Kong, expected to finish early next year, which could raise new money. Its HT Supreme drug-eluting stent also won approval in Paraguay. Both broaden funding and sales, though the H-share plan is still pending.
It shows a new funding route and another overseas market.

August 202624 Jul – 9 Oct 2026

▲4

Sino Medical's profit surge and overseas approvals drive the story

First-half profit jumps on coronary and neuro product sales Sino Medical said first-half 2026 net profit should rise about 264% to 50.3 million yuan, as its coronary products sold more and new neuro products grew strongly, with revenue up about 27% and costs controlled. That profit growth is the main force pushing the stock up.
This is the core earnings driver behind the period's move.
Interim report confirms the profit jump and healthy cash flow The actual interim report matched the forecast: 305 million yuan revenue, 50.3 million yuan net profit, and 94 million yuan of cash coming in from operations. A low debt ratio and 70% gross margin show the business is profitable and not stretched, supporting the shares.
It confirms the earnings surprise with real numbers and cash flow.
Overseas approvals open new markets for heart devices Sino Medical won registration for its coronary balloon catheter in Vietnam and Colombia, letting it sell these heart products in those countries. Each approval is a small but real step in overseas expansion, adding future sales that support the stock price.
New market approvals are a fresh growth path for the company.
H-share listing plan and Paraguay stent approval add capital and reach Sino Medical is filing to issue H-shares in Hong Kong, expected to finish early next year, which could raise new money. Its HT Supreme drug-eluting stent also won approval in Paraguay. Both broaden funding and sales, though the H-share plan is still pending.
It shows a new funding route and another overseas market.

Latest24 Jul – 9 Oct 2026

▲4

Sino Medical's profit surge and overseas approvals drive the story

First-half profit jumps on coronary and neuro product sales Sino Medical said first-half 2026 net profit should rise about 264% to 50.3 million yuan, as its coronary products sold more and new neuro products grew strongly, with revenue up about 27% and costs controlled. That profit growth is the main force pushing the stock up.
This is the core earnings driver behind the period's move.
Interim report confirms the profit jump and healthy cash flow The actual interim report matched the forecast: 305 million yuan revenue, 50.3 million yuan net profit, and 94 million yuan of cash coming in from operations. A low debt ratio and 70% gross margin show the business is profitable and not stretched, supporting the shares.
It confirms the earnings surprise with real numbers and cash flow.
Overseas approvals open new markets for heart devices Sino Medical won registration for its coronary balloon catheter in Vietnam and Colombia, letting it sell these heart products in those countries. Each approval is a small but real step in overseas expansion, adding future sales that support the stock price.
New market approvals are a fresh growth path for the company.
H-share listing plan and Paraguay stent approval add capital and reach Sino Medical is filing to issue H-shares in Hong Kong, expected to finish early next year, which could raise new money. Its HT Supreme drug-eluting stent also won approval in Paraguay. Both broaden funding and sales, though the H-share plan is still pending.
It shows a new funding route and another overseas market.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.